FDA 483 - ICON plc - October 24, 2025

An FDA inspection of ICON plc's bioanalytical facility in Assen, Netherlands, revealed a significant deficiency in method validation activities. The firm failed to adequately evaluate the specificity of bioanalytical methods for certain compounds in the presence of all co-administered medications during a study. This indicates a potential issue with the reliability of the analytical data.